Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 47Etoposide 46durvalumab 28atezolizumab 27Cisplatin 21Topotecan 19pembrolizumab 15PM 01183 15Nivolumab 12Specimen Handling 11Drug Therapy 10anlotinib 9Radiotherapy 9Paclitaxel 9Temozolomide 8Magnetic Resonance Spectroscopy 8AMG 757 8Radiosurgery 7Platinum 7Irinotecan 7toripalimab 6olaparib 6Biopsy 6Ipilimumab 5Injections 5Docetaxel 5Bevacizumab 5trilaciclib 4tremelimumab 4tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × BAY 1895344 × 1 year × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡